Janssen In this exclusive and wide-ranging interview, Janssen’s EMEA head Kris Sterkens outlines the company’s strategies in Europe, its increasing embrace of digital solutions, and the shift toward pre-emptive and precision treatments. Sterkens also highlights how Janssen is positioning itself in the emerging markets under his remit and how the ongoing…
Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co. Now that we have all this data,…
FT These insights come from Richie Etwaru, the CEO of Hu-Manity.co, known for pursuing the 31st Human Right “everyone has the right to legal ownership of their inherent human data as property.” There is a tremendously broken data supply chain, which will trigger social uproar when the public are made…
Opinion Holmusk’s Nawal Roy highlights the increasing recognition of the value of real-world evidence (RWE) by both innovative pharma companies and drug regulators and its potential to increase market capture and profitability. RWE has the potential to expand the market size of a disease and accelerate market capture of a…
Opinion Tom Achoki of Mass Sciences explores the possibilities that better access to high-quality real-world data will create for accelerating novel drug discovery and ultimately improving patient outcomes. Proactive decision makers within the biopharmaceutical industry need to find innovative ways to bridge the existing RWD gaps within their organization The…
France Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the latest projects the company is working on to digitally transform healthcare. Access to healthcare is a critical issue around…
Opinion The Foundations for Evidence-Based Policy-Making Act, recently signed into law in the USA, stands to make government data more accessible; thereby allowing researchers, statisticians and others inside and outside of government to make better, and evidenced-based, policy decisions. Carla Smith outlines the scope of the Act and its potential implications…
Korea Steve Hong, CEO, and Tony Lim, vice president & COO of Lemon Healthcare, lift the lid on the new streamlined hospital data services they are offering, and the benefits to speed and cost effectiveness that they will bring to healthcare providers and patients. Lim also reveals his strategy to expand…
Trends As we move further into 2019, Emmanuel Fombu, MD, MBA: Author and Global Commercial Strategy and Digital Innovation Leader at Johnson and Johnson, reflects on what to expect from the rest of the year and beyond in the pharmaceutical landscape. The battle for market share in the future will likely…
Opinion Deloitte’s Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019’s industry trends. For companies to address mounting pressures, a digital-first mindset will be required to make business operations more efficient and bring transformational therapies to the market. Digital…
Opinion Nawal Roy is founder and CEO of Holmusk, a company dedicated to building one of the world’s largest real-world evidence platforms for neurosciences. Here, Nawal Roy discusses the potential for real-world evidence to optimise drug life-cycle management. Use of real-world evidence (RWE) can modernize the process of drug research, development and delivery. The…
Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option. The key to success for pharma players is to sponsor the accumulation of…
See our Cookie Privacy Policy Here